NCT03281824View on ClinicalTrials.gov

Clinical Study of ALT-P7 to Determine Safety, Tolerability and Pharmacokinetics in Breast Cancer Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

January 11, 2018

Primary Completion Date

March 12, 2020

Study Completion Date

January 15, 2021

Conditions
HER2-positive Breast Cancer
Interventions
BIOLOGICAL

ALT-P7 (HM2-MMAE)

Antibody-Drug Conjugate

Trial Locations (1)

Unknown

Alteogen, Daejeon

Sponsors

Lead Sponsor

Alteogen, Inc.
All Listed Sponsors
lead

Alteogen, Inc.

INDUSTRY

NCT03281824 - Clinical Study of ALT-P7 to Determine Safety, Tolerability and Pharmacokinetics in Breast Cancer Patients | Biotech Hunter | Biotech Hunter